Loncar Cancer Immunotherapy Etf Ten Year Return
| CNCR Etf | USD 10.72 0.19 1.80% |
Loncar Cancer Immunotherapy fundamentals help investors to digest information that contributes to Loncar Cancer's financial success or failures. It also enables traders to predict the movement of Loncar Etf. The fundamental analysis module provides a way to measure Loncar Cancer's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Loncar Cancer etf.
Loncar |
Loncar Cancer Immunotherapy ETF Ten Year Return Analysis
Loncar Cancer's Ten Year Return shows the total annualized return generated from holding a fund for the last 10 years and represents fund's capital appreciation, including dividends losses and capital gains distributions. This return indicator is considered by many investors to be the ultimate measures of fund performance and can reflect the overall performance of the market or market segment it invests in.
More About Ten Year Return | All Equity Analysis
Ten Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Although Ten Year Fund Return indicator can give a sense of overall fund long-term potential, it is recommended to compare funds performances against other similar funds or market benchmarks for the same 10-year interval.
| Competition |
Based on the latest financial disclosure, Loncar Cancer Immunotherapy has a Ten Year Return of 0.0%. This indicator is about the same for the Loncar Investments average (which is currently at 0.0) family and about the same as Health (which currently averages 0.0) category. The ten year return for all United States etfs is 100.0% higher than that of the company.
Loncar Ten Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Loncar Cancer's direct or indirect competition against its Ten Year Return to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of Loncar Cancer could also be used in its relative valuation, which is a method of valuing Loncar Cancer by comparing valuation metrics of similar companies.Loncar Cancer is currently under evaluation in ten year return as compared to similar ETFs.
Fund Asset Allocation for Loncar Cancer
The fund invests 99.87% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides Loncar Cancer's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
Loncar Fundamentals
| Price To Earning | 24.63 X | |||
| Price To Book | 1.99 X | |||
| Price To Sales | 1.24 X | |||
| Number Of Employees | 395 | |||
| Beta | 0.92 | |||
| Total Asset | 20.52 M | |||
| One Year Return | (32.60) % | |||
| Three Year Return | (16.60) % | |||
| Five Year Return | (8.90) % | |||
| Net Asset | 20.52 M | |||
| Last Dividend Paid | 0.35 | |||
| Equity Positions Weight | 99.87 % |
About Loncar Cancer Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Loncar Cancer Immunotherapy's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Loncar Cancer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Loncar Cancer Immunotherapy based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Loncar Cancer Immuno is a strong investment it is important to analyze Loncar Cancer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Loncar Cancer's future performance. For an informed investment choice regarding Loncar Etf, refer to the following important reports: Check out Loncar Cancer Piotroski F Score and Loncar Cancer Altman Z Score analysis. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
The market value of Loncar Cancer Immuno is measured differently than its book value, which is the value of Loncar that is recorded on the company's balance sheet. Investors also form their own opinion of Loncar Cancer's value that differs from its market value or its book value, called intrinsic value, which is Loncar Cancer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Loncar Cancer's market value can be influenced by many factors that don't directly affect Loncar Cancer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Loncar Cancer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Loncar Cancer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Loncar Cancer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.